Medicus Pharm submitted a product development plan to the FDA for an Investigational New Animal Drug designation.

A novel immuno-PET/CT imaging technique has identified and validated a potent biomarker for nasopharyngeal cancer (NPC). The biomarker, CD70, is highly and constantly expressed in NPCs, and ...